Virotherapy: The next addition to the standard of care for glioblastoma?

Author(s):
Broekman, M.L.D.; Nieland, L.; Hoeben, R.C. (0000-0001-9443-8377)
Published
2022
Publication type
Other

Abstract

A recent Nature Medicine article reported a phase II single-arm trial assessing the efficacy of a triple-mutated, third-generation oncolytic herpes simplex virus type 1 in patients with recurrent or residual glioblastoma. We discuss the results and highlight the potential of locally administered virus-based therapies to fight these le-thal tumors.

Date issued
2022-10-10
Language
English
Publisher
CELL PRESS
hdl
1887/3512677
doi
10.1016/j.ccell.2022.09.003